You don't see efficacy so early in Ph1 clinical trial which is why the lead presenter also Tweet about it during the Conference early this year, you usually see them in Ph2 after dosage escalation and OBD has been determined in Ph1 and then advanced to Ph3 after seeing efficacy in Ph2 and there is plan for Azer-Cel to go through the registrational clinical trial.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)